Literature DB >> 22190592

Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Claudia Nunes1, Ryan Wong, Malcolm Mason, Chris Fegan, Stephen Man, Chris Pepper.   

Abstract

PURPOSE: Patients with chronic lymphocytic leukemia (CLL) display immune deficiency that is most obvious in advanced stage disease. Here we investigated whether this immune dysfunction plays a pathologic role in the progression of early stage disease patients. EXPERIMENTAL
DESIGN: We carried out eight-color immunophenotyping analysis in a cohort of 110 untreated early stage CLL patients and 22 age-matched healthy donors and correlated our findings with clinical outcome data.
RESULTS: We found a significant reduction in naive CD4(+) and CD8(+) T cells in CLL patients. Only the CD4(+) subset showed significantly increased effector memory cells (T(EM) and T(EMRA)) in the whole cohort (P = 0.004 and P = 0.04, respectively). However, patients with inverted CD4:CD8 ratios (52 of 110) showed preferential expansion of the CD8 compartment, with a skewing of CD8(+) T(EMRA) (P = 0.03) coupled with increased percentage of CD57(+)CD28(-)CD27(-) T cells (P = 0.008) and PD-1 positivity (P = 0.027), consistent with a replicative senescence phenotype. Furthermore, inverted CD4:CD8 ratios were associated with shorter lymphocyte doubling time (P = 0.03), shorter time to first treatment (P = 0.03), and reduced progression-free survival (P = 0.005).
CONCLUSIONS: Our data show that the emergence of CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with more aggressive clinical disease. Importantly, these findings were independent of tumor cell prognostic markers and could not be accounted for by patient age, changes in regulatory T-cell frequency, or cytomegalovirus serostatus (n = 217).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22190592     DOI: 10.1158/1078-0432.CCR-11-2630

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  60 in total

1.  B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia.

Authors:  Nadja Zaborsky; Claudia Holler; Roland Geisberger; Daniela Asslaber; Franz Josef Gassner; Viktoria Egger; Josephina Piñón-Hofbauer; Thomas Kocher; Tanja Nicole Hartmann; Richard Greil; Alexander Egle
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

2.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

3.  Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Authors:  Fabienne McClanahan; John C Riches; Shaun Miller; William P Day; Eleni Kotsiou; Donna Neuberg; Carlo M Croce; Melania Capasso; John G Gribben
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 4.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

Review 5.  Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.

Authors:  Yi Xia; L Jeffrey Medeiros; Ken H Young
Journal:  Biochim Biophys Acta       Date:  2015-10-16

Review 6.  Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Authors:  Andres Chang; Danielle Schlafer; Christopher R Flowers; Pamela B Allen
Journal:  Expert Opin Investig Drugs       Date:  2017-12-24       Impact factor: 6.206

Review 7.  Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.

Authors:  Kamira Maharaj; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2017-09-26

Review 8.  Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia.

Authors:  Audrey Mohr; Yves Renaudineau; Cristina Bagacean; Jacques-Olivier Pers; Christophe Jamin; Anne Bordron
Journal:  Oncoimmunology       Date:  2016-03-16       Impact factor: 8.110

9.  Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Authors:  Candida Vitale; Lorenzo Falchi; Elisa Ten Hacken; Hui Gao; Hila Shaim; Katrien Van Roosbroeck; George Calin; Susan O'Brien; Stefan Faderl; Xuemei Wang; William G Wierda; Katayoun Rezvani; James M Reuben; Jan A Burger; Michael J Keating; Alessandra Ferrajoli
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

Review 10.  Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.

Authors:  Farhad Jadidi-Niaragh; Ghasem Ghalamfarsa; Mehdi Yousefi; Mina Hajifaraj Tabrizi; Fazel Shokri
Journal:  Tumour Biol       Date:  2013-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.